Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (Note: The metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) on June 16, 2017. The report details the entry into a Material Definitive Agreement regarding the acquisition of EUROIMMUN Medizinische Labordiagnostika AG ("EUROIMMUN").
Key Financial Metrics and Transaction Terms
- Transaction Type: Share Sale and Transfer Agreement to acquire up to 100% of EUROIMMUN.
- Total Consideration: Up to €1,200,000,000 in cash for 100% equity participation.
- Payment Terms: Cash payment without interest, subject to tax withholding.
- Escrow Fund: €100,000,000 to be withheld from closing proceeds for potential breach of warranty claims.
- Financial Performance: The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for PerkinElmer or EUROIMMUN.
Material Changes and Conditions
The primary material change is the initiation of the acquisition process. The consummation of the transaction is subject to customary conditions, including the expiration of specified antitrust waiting periods. The agreement includes a two-year termination window if closing conditions are not fulfilled or waived, unless the failure is due to a breach by the withdrawing party.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The filing contains statements regarding the potential consummation of the acquisition, which are subject to risks and uncertainties.
- Key Risks: Failure to satisfy conditions precedent (e.g., antitrust approvals) could prevent the acquisition from closing.
- Warranty Limitations: Claims for breach of certain warranties are limited to two years post-closing and capped at the €100,000,000 escrow amount. Fundamental representation breaches are capped at the total amount payable to the controlling shareholders.
- Management Commentary: The filing does not provide specific management commentary on future operational guidance beyond the transaction details.
Investor Verification Checklist
- Verify the current corporate name of the registrant (PerkinElmer, Inc. vs. REVVITY, INC.) to ensure accurate historical tracking.
- Monitor regulatory filings for the status of antitrust waiting periods and other closing conditions.
- Review the definitive agreement for specific details on the option agreements with minority shareholders of EUROIMMUN.
- Assess the impact of the €100,000,000 escrow holdback on immediate cash flow upon closing.
- Confirm the final purchase price and percentage of equity acquired once the transaction closes.